Iron Deficiency Screening in Patients Admitted with Acute Heart Failure Decompensation

Abstract Correction of iron deficiency (ID) with intravenous iron among patients with heart failure (HF) may improve outcomes but is rarely assessed in real-world studies. Hospital admission for decompensated HF presents an opportunity to identify patients for treatment of ID. Of 2,275 patient admissions for decompensated HF, iron studies were available for 526 (23.1%) and ID was identified in 332 (63.1%) patients. Iron replacement was oral in 241 (10.6%) or intravenous in 285 (12.5%) with 132 (46.3%) patients receiving treatment during the admission. Anemia, chronic kidney disease stage 3 (CKD3), and low mean corpuscular volume (MCV) were associated with a higher odds of iron study availability while age was associated with lower odds. Frequency of assessment of ID in HF patients remains low. Predictors of iron status assessment indicate that factors related to anemia rather than HF are likely responsible for iron status assessment among these patients.

Authors

Publication Details

Journal
Journal of Cardiovascular Translational Research
Published
2026-05-19
DOI
https://doi.org/10.1007/s12265-026-10774-8
Primary Topic
Erythropoietin and Anemia Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Iron Deficiency Screening in Patients Admitted with Acute Heart Failure Decompensation

Yassar Nabeel, Lawrence A Frazee, Olivia Palladino, Alex M. Sindledecker
Journal of Cardiovascular Translational Research
Erythropoietin and Anemia Treatment
article

Iron Deficiency Screening in Patients Admitted with Acute Heart Failure Decompensation

Yassar Nabeel, Lawrence A Frazee, Olivia Palladino, Alex M. Sindledecker
article en

Abstract

Abstract Correction of iron deficiency (ID) with intravenous iron among patients with heart failure (HF) may improve outcomes but is rarely assessed in real-world studies. Hospital admission for decompensated HF presents an opportunity to identify patients for treatment of ID. Of 2,275 patient admissions for decompensated HF, iron studies were available for 526 (23.1%) and ID was identified in 332 (63.1%) patients. Iron replacement was oral in 241 (10.6%) or intravenous in 285 (12.5%) with 132 (46.3%) patients receiving treatment during the admission. Anemia, chronic kidney disease stage 3 (CKD3), and low mean corpuscular volume (MCV) were associated with a higher odds of iron study availability while age was associated with lower odds. Frequency of assessment of ID in HF patients remains low. Predictors of iron status assessment indicate that factors related to anemia rather than HF are likely responsible for iron status assessment among these patients.

Journal of Cardiovascular Translational ResearchVol. 19(1)
Good health and well-being
Openalex Percentile: Top 5%
Erythropoietin and Anemia Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Iron Deficiency Screening in Patients Admitted with Acute Heart Failure Decompensation — Yassar Nabeel, Lawrence A Frazee, et al. · Journal of Cardiovascular Translational Research (2026) | TGRS Research Map | TGRS